Departed
Dr. Daniel Teper
President
IVF ·
INVO Fertility, Inc.
On May 28, 2025, Dr. Daniel Teper resigned as President of the Company.
IVF
INVO Fertility, Inc.
Saved in this browser
Ready 8-Ks
28
Latest filing
Apr 29, 2026 23:59 UTC
Top materiality
0.85
Event mix
other_material ×16 · m_and_a ×3 · earnings ×3
Sentiment
2 pos · 5 neg · 21 neu
Latest earnings
reported 2025-Q3
Executive change
recent →
Recent 8-K filings for IVF
Highest-materiality recent filing
INVO Fertility shareholders approve increase in authorized shares from 6.25M to 250M and warrant issuance
- Authorized common shares increased from 6,250,000 to 250,000,000 via Certificate of Amendment filed Jan 22.
- Shareholders approved issuance of up to 4,733,728 shares upon exercise of warrant from Dec 2025 private placement.
-
INVO Fertility receives Nasdaq deficiency notice for late 10-K filing
Received Nasdaq notice on April 23, 2026, for failing to file 2025 Form 10-K by April 15, 2026.
-
INVO Fertility to effect 1-for-5 reverse stock split effective March 27, 2026
Reverse split ratio: 1-for-5; effective 12:01 a.m. ET on March 27, 2026.
-
INVO Fertility closes acquisition of Family Beginnings clinic for $760K (cash + preferred stock)
Total purchase price $760K: $360K cash (net $210K after $150K holdback) plus 400 shares of Series D Preferred ($400K).
-
INVO Fertility raises $7.5M via warrant exercise; issues new warrants for 9.5M shares
Holder exercises 4,733,728 existing warrants at reduced $1.59 price, gross proceeds ~$7.5M.
-
Authorized common shares increased from 6,250,000 to 250,000,000 via Certificate of Amendment filed Jan 22.
-
INVO Fertility appoints Terah Krigsvold as CFO, Andrea Goren moves to Chief Business Officer
Terah Krigsvold promoted from controller to CFO effective Dec 30, 2025; base salary $250k, bonus up to 50%.
-
Total purchase price $750K: $350K cash (less $150K holdback) plus $400K in Series D convertible preferred stock.
-
INVO Fertility raises $4.0M in private placement of stock and warrants
Gross proceeds ~$4.0M from 2,366,864 shares/pre-funded warrants plus 4,733,728 common warrants at $1.69 combined.
-
INVO Fertility announces 1-for-8 reverse stock split effective Nov 28, 2025
Every 8 pre-split shares converted into 1 share; fractional shares rounded up.
-
INVO Fertility Q3 revenue up 23% to $1.76M; net loss widens to $2.6M
Revenue $1,757,094 (+23% YoY); clinic revenue $1,722,223 (+21% YoY).
-
Institutional investor exercised Additional Investment Right to buy 500 shares of Series C-2 Preferred for $500,000 cash.
-
INVO Fertility issues $200k Series C-2 Preferred to existing holder at $0.6643 conversion
Institutional investor exercised Additional Investment Right to acquire 200 shares of C-2 Preferred for $200,000 cash.
-
INVO Fertility settles litigation with Dr. Pritts for $6.01M; issues preferred shares
Settlement requires Wood Violet to pay Dr. Pritts $6,010,000 in installments through Dec 2026, with $1M already paid.
-
INVO Fertility exchanges $1.34M convertible debenture for Series C-2 convertible preferred shares
Five Narrow Lane LP exchanged its 7% convertible debenture due Feb 2026 for Series C-2 Preferred stock with $1,334,000 stated value.
-
INVO Fertility restructures Decathlon loan; payment up $20k/mo, interest multiples raised
Monthly loan payment increased by $20,000 beginning August 2025.
-
INVO Fertility issues $200k Series C-2 Preferred to existing holder, conversion price $0.7362
Institutional investor exercises Additional Investment Right, buys 200 shares of C-2 Preferred for $200,000 cash.
-
INVO Fertility dismisses M&K, appoints Withum as new auditor
M&K dismissed effective Sept 5, 2025; audit committee approved change.
-
Principal reduced to $1,751,343.75 via $1,300,000 exchange for 325 Series C-2 Preferred shares with $1.3M stated value.
-
INVO Fertility Q2 2025 revenue up 1% to record $1.86M, net loss widens to $3.2M
Q2 2025 revenue $1,863,654 (record), up 1% YoY; clinic revenue $1,832,094 up 1%.
-
INVO Fertility issues $200K Series C-2 Preferred shares, conversion price at $1.8909
Institutional investor exercises Additional Investment Right to purchase 200 Series C-2 Preferred shares for $200,000 cash.
-
INVO Fertility authorized shares increased to 50M from 1.39M; issues $200k preferred
Shareholders approved increasing authorized common shares from 1,388,888 to 50,000,000; vote: 643,612 for, 219,764 against, 5,008 abstain.
-
INVO Fertility 1-for-3 reverse stock split effective July 21, 2025 to meet Nasdaq bid price rule
Reverse split at 1:3 effective pre-market July 21, 2025; new CUSIP 44984F708.
-
INVO Fertility adjourns annual meeting to July 23; vote on proposal 3 pending
Annual meeting initially held June 25; votes on proposals 1,2,4,5,6,7,8 completed.
-
INVO Fertility amends SPA, exchanges $1.8M debenture for preferred shares, issues inducement shares
Amendment to SPA allows Holder to exchange up to $10M of C-2 Preferred for Debenture, minimum $200k.
-
All five director nominees elected: Davis, Messina, Ryan, Shum, Szot.
-
INVO Fertility divests majority holdings in NTI, retains preferred stake and note
Effective June 2, 2025, INVO redeemed all Series C-1 Preferred for 3,227,813 shares of NTI Class A Common, ceasing to hold NTI common.
-
INVO restructures NTI holdings with $4.8M note and preferred stock amendments
Exchanged 801,196 NTI shares (19.9% stake) for 6,300 NTI Series A Preferred shares, $1,000 stated value each.
-
INVO Fertility Q1 2025 revenue up 4% but net loss widens to $17.4M on $14.6M impairment
Revenue $1.64M, +4% YoY; clinic revenue from consolidated centers +5% to $1.62M.
Executive changes
Earnings & guidance
Materiality & sentiment trend
Max materiality 0.85 · Median 0.60 · Most common event other_material